

Hypothesis and Aim

IM restoration using FMT would have a beneficial effect on liver damage, being a useful therapeutic strategy in NAFLD. The use of the Covergel platform would increase the effectiveness of TMF by improving the colonization of the transplanted microbiota.

In an animal model of steatohepatitis with fibrosis we aimed to assess: > The role of the intestinal microbiota in the mechanisms leading to steatosis and fibrosis. > The effectiveness of Covergel for the delivery of FMT with single colonoscopy vs the standard method

Method



- 30 Male S-D rats (100-120 g), (high fat, high fructose, high cholesterol diet), CCl₄ in corn oil
- Drug-eluting platform COVERGEL (hyaluronic acid, methyl cellulose, pluronic) • Olympus bronchoscope, catheter (2.5 mm diameter)
- SPF Facilities CMCiB





Fecal microbiota trasplant using endoscopic-placement hydrogel reduces liver fibrosis with no changes in steatosis in a rat model of steatohepatitis with fibrosis

Introduction

The intestinal microbiota (IM) has emerged as a key factor in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) in addition genetic predisposition, to environmental factors and insulin resistance.

This has led to propose the restoration of healthy intestinal microbiota (IM) with fecal microbiota transplantation (FMT) as a promising therapeutic strategy in the treatment of this disease. However, effective colonization of the colon is difficult to achieve.

Our group has developed a hydrogel for endoscopic placement (Covergel) capable of releasing substances, which, used as a vehicle, could improve the effectiveness of FMT



after colonic cleaning with 60 mL of warm irrigation water.



GROUP	Albumin mg/dL	Bilirrubin mg/dL	Alkaline Ph. U/L	AST U/L	ALT U/L	HDL mg/dL	LDL mg/dL	Triglycerides mg/dl	HOMA IR
Healthy feces saline	31,8±1,7	0,16±0,4	305,0±83,9*	102,7±39,5	56,63±7,2*	42,1±7,7*	16,4±7,3*	63,2±19,2	4,44±3,6
Healthy feces covergel	30,6±1,3	0,15±0,5	157,0±30,9#	96,4±52,6	46,5±12,9*	35,7±5,7*	22,3±8,7	73,7±13,5	5,45±3,3
NASH feces covergel	30,4±1,3	0,15±0,4	265,1±51,6*	87,5±31,7	42,6±5,8*	40,9±3,8*	19,1±4,6*	83,4±12,2	11,08±23,2
Healthy rats	31,7±1,6	0,17±0,3	88,0±11,5	72,8±15,1	30,2±3,4	58,1±5,3	24,3±4,2	78,7±12,0	3,67±3,5

*p<0,05 vs group 4, *p<0,05 vs groups 1 and 3

Conclusions

- attenuation of the ongoing steatosis.



BARTOLÍ R^{1,2}, IBORRA I^{1,3}, BARBOSA S⁴, DOLADÉ M⁵, FORTUNY M⁶, MASNOU H^{2,3}, MORILLAS RM^{2,3}

1.Health Research Institute Germans Trias i Pujol (IGTP), Hepatology Unit. Gastroenterology Derpartment, Badalona, Spain, 2.Centre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd, 3.Hospital Germans Trias i Pujol, Hepatology Unit. Gastroenterology Derpartment, Badalona, Spain, 4. Universitat Autónoma de Barcelona, Department of Cell Biology, Physiology and Immunology, Faculty of Veterinary Medicine, Bellaterra, Spain, 5.Hospital Germans Trias i Pujol, Clinical Analysis and Biochemistry Department, Badalona, Spain, 6.Hospital Germans Trias i Pujol, Gastroenterology Department, Badalona, Spain

Gut-Liver axis

- Choline metabolism
- Biliary acids conjugation
- Short-chain fatty acids metabolism
- Endogenous ethanol production
- Tight-junction disruption
- Inflammasome disfunction (mostly NLRP 3 and 6)
- PAMPs: Mostly LPS but also peptidoglycans, viral RNA • Secretion of proinflammatory cytokines from GALT: TNF-α,
- IL-1, IL-6, TGF-β
- Activation though toll-like receptors (TLR) 4, 2 and 5 • Secretion of cytokines by Kupffer cells and monocytes
- Stimulation of stellate cells (Ito cells)

HEPATIC INJURY







The TMF do not promote significant changes in steatosis degree.

> Fecal microbiota transplantation using Covergel significantly reduces liver to weight ratio, normalizes phosphatase alkaline and LDL-cholesterol and significantly reduces fibrosis without significant

>The use of Covergel would be an advantage, since the prolonged residence time of the hydrogel adhered to the mucosa would facilitate microorganisms colonization with a single colonoscopy.













Scan to ownload tl poster





INTERNATIONAL R CONGRESS THE







Endoscopic placement hydrogel *Covergel*[®]

A reverse thermal gelation composition developed by our group (liquid at room temperature and solid at 37°C) Patented Class III MD



Biocompatible & Biodegradable Appropriate viscosity Appropriate adhesion capacity Refractory to bacterial degradation Easy to apply through endoscope Able to deliver molecules and cells

Standard FMT achieves a non-significant improvement in hepatic fibrosis (1 vs 3, p=0.084). In contrast, TMF-Covergel shows a significant improvement in it (2 vs 3, p=0.001). In addition, the reduction in fibrosis is significantly higher with TMF-Covergel compared to standard TMF (2 vs 1, p=0.034).

References

1. Leylabadlo HE et al. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. European Journal of Clinical Microbiology & Infectious Maeso-Diaz R et al. New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease. Cells 2019, 8, 1062
Bon I et al. Development and Characterization of a New Endoscopic Drug-Eluting Platform With Proven Efficacy in Acute and Chronic Experimental Colitis. Front Med

Contact information Rosa Mª Morillas Cunill *rmorillas.germanstrias@gencat.cat* Ignacio Iborra Chaques nachoiborra@gmail.com